Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy
An analysis of the Pollux trial
Maiese, E. M., Graham, CN., Hawe, E., Le Moine, J-G., Abraham, I., & Senbetta, M. (2017). Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: An analysis of the Pollux trial. Blood, 130.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.